


Policies to reduce drug expenditure without harming patients



Daniel Goldstein MD is a medical oncologist at Rabin Medical Center, a senior lecturer in Medical Oncology at Tel Aviv University and medical director of drug and technology policies in the community division of Clalit Health Services. He is responsible for developing policies that impact 4 million insurees. His area of research is in the global economics of cancer care, focusing on cost-effectiveness, budget impact and affordability.



Dr Goldstein will discuss pharmacologic opportunities to reduce cancer drug expenditure without harming patient outcomes.

He will discuss the used of weight-based immunotherapy, used in multiple cancers, which can save 25% of resources.



He will also discuss the existence of class effects, which can also lead to significant cost savings (of up to 30%).



Please register for this seminar at 4pm (Irish time) on the 23rd of May 2022 here:

[REGISTRATION](#)



**The seminar will be introduced by Dr Jonathan Briody - health economist in the Division of Population Health Sciences, RCSI and researcher on the EU Horizon 2020 Project COLOSSUS. Though not directly linked to Dr Goldstein's work, COLOSSUS includes an important health economics aspect. Dr Briody will give a brief introduction to the COLOSSUS project during the seminar.*

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 754923. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.



RCSI